JOHNSON & JOHNSON is 1.4x more valuable than AbbVie Inc. by market capitalization ($573.98 B vs $399.47 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | ABBV | JNJ |
|---|---|---|
| Market cap | $399.47 B | $573.98 B |
| US-listed rank | #28 | #20 |
| Revenue (latest FY) | $61.16B | $94.19B |
| Net income (latest FY) | $4.23B | $26.80B |
| Net margin | 6.9% | 28.5% |
| P/E (trailing FY) | 94.5 | 21.4 |
| SEC filings | 1,008 | 984 |
JOHNSON & JOHNSON is 1.4x more valuable than AbbVie Inc. by market capitalization ($573.98 B vs $399.47 B).
In their latest fiscal years, AbbVie Inc. reported $61.16B in revenue while JOHNSON & JOHNSON reported $94.19B.
Full pages: AbbVie Inc. and JOHNSON & JOHNSON, or browse the full rankings.